ERBB2 and breast cancer: However, some multicenter trials that aimed at investigating whether patients with HER2-pos CTCs but HER2-neg PT could benefit from HER2-targeted therapies (NSABP B47 and the Treat-CTC trial) failed to confirm the hypothesis that adjuvant trastuzumab can benefit women with HER2 non-amplified early BC [32–34].